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ABSTRACT 
 
Melanin-concentrating hormone (MCH) is integral to the regulation of human appetite. 
MCH targets G protein-coupled receptors in the brain and peripheral tissues. When MCH 
receptor 1 binds MCH on the surface of cells, it activates multiple signaling pathways, then 
desensitizes. Internalization of MCH-bound MCHR1 is only thought to be partially responsible 
for the loss of MCH signaling capacity of cells. Previous research has shown that MCH receptors 
are enriched in caveolae and specifically complex with caveolin-1. Caveolin-1 is a key structural 
component of caveolae, which are cholesterol-based lipid rafts that are known for concentrating 
signaling molecules and clathrin-independent endocytosis. This study aims to investigate how 
MCH signaling would be affected if MCH receptors weren’t enriched in these regions. 
Pharmacological treatments were used to achieve this goal as caveolae formation was disrupted 
with the antibiotic nystatin, a cholesterol inhibitor. It has been shown that sodium carbonate-
based extraction procedure followed by flotation on sucrose density centrifugation isolates 
caveolae from other cell contents. Caveolae-isolation procedures to detect caveloin-1 were 
undertaken to indicate that untreated BHK-570 cells contained caveolin-1 in fractions 4 and 5 of 
the sucrose gradients while a gradient shift of caveolin-1 to fractions 7-10 in nystatin-treated 
cells occurred. Such shift confirmed that there was a partial disruption of caveolae within the 
treated cells. Future experiments will test whether other pharmacological inhibitors such as 
filipin and methyl-β-cyclodextrin as well as caveolin-1 RNAi are better able to deplete caveolae 
from cells as well as their impact on MCH signaling. 
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INTRODUCTION 
 
Obesity 
 
Obesity is caused by an accumulation of adipose tissue resulting in the impairment of 
one’s health. It is estimated that incidences and diseases such as strokes, coronary artery disease, 
and type II diabetes have increased over the past decade in America due to the rise in the 
prevalence of obesity. To be considered obese a person must have a body mass index (BMI) of 
≥30 (Vemmos et al. 2011). Currently, one-third of Americans have a BMI above this number and 
experience numerous acute and chronic problems and an attenuation of life expectancy 
(Kopelman 2000).   
 Obesity in America is becoming so prevalent that is it reaching epidemic proportions. By 
2030 it is estimated that 42% of adult Americans will fit the criteria for being obese (Ogden et al. 
2014). A 10% increase in incidence over the next 15 years will continue to place a heavy burden 
on the lives of those afflicted with obesity and the healthcare system as a whole. With more of 
the population living unhealthy lives, doctors will begin to see an increase in obesity-related 
problems that will strain the funds of the United States healthcare system (Finkelstein et al. 
2009). 
 The estimated annual medical cost of obesity in the United States was $147 billion in 
2008. Furthermore, the medical costs for people who are obese were $1,429 higher than those of 
normal weight per year. These costs accrue because of a higher use of services and medical 
treatments that were aimed at reducing the adverse affects of obesity either with surgical 
procedures or pharmacological treatments (Finkelstein et al. 2009). It is the hope that with 
implementation of the Affordable Health Care Act, there will be broad access to primary medical 
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services and educational material that will act as preventative measures to begin to reduce both 
the financial and personal cost of obesity (Finkelstein et al. 2009; Derksen 2013).  
A challenge with reducing obesity is the numerous facets of the disease. There is a strong 
correlation between obesity and genetics; however environmental factors can also impact an 
individual. The family, culture, and ethnicity that a person belongs too can directly affect how a 
person interacts with food and energy expenditure. For instance, cultures that emphasize large 
meals and embrace a sedentary lifestyle may be more prone to obesity-related diseases 
(Kopelman 2000). Non-Hispanic blacks have the highest age-adjusted rates of obesity (47.8%) 
followed by Hispanics (42.5%), non-Hispanic whites (32.6%), and non-Hispanic Asians (10.8%) 
while obesity is higher among middle-aged adults, 40-59 years old (39.5%) than among younger 
adults, age 20-39 (30.3%) or adults over 60 or above (35.4%) adults  (Finkelstein et al. 2009). 
Obesity results from an imbalance in energy intake but the cause of that imbalance must be 
addressed in order to combat this epidemic.   
Regulation of Food Intake  
 Food consumption is regulated within the human body by neurotransmitters, signaling 
peptides, and feedback loops that allow the body to either potentiate satiety or hunger signals. 
When the body experiences a state of fasting or ingestion, the brain is able to determine its 
nutritional state through signals from the liver, gastrointestinal tract (GIT), pancreas and adipose 
tissue. Other interpretations made by the brain concerning the energy needs of the body are 
carried out by hormones such as leptin and ghrelin (Williams, Harrold, and Cutler, 2000; Woods 
et al. 1998).  
The hypothalamus and the brain stem are the main centers of the brain associated with 
food intake. The afferent nerves associated with the liver, Gastro Intestinal Tract, pancreas and 
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adipose tissue are integrated with the hypothalamus and other higher ordered brain systems that 
control reward and learning behavior. The arcuate nucleus (ARC) of the hypothalamus drives 
both fasting and feeding within the body. Orexingenic neurons present in the ARC express 
neuropeptide Y (NPY) and agouti-related protein both of which potentiate feeding signals. The 
ARC also contains anorexigenic neurons that decrease feeding behavior by releasing alpha-
melanocyte stimulating hormone. ARC also plays a role in paraventricular nuclei stimulation 
within the hypothalamus, whose purpose is to regulate energy expenditure (Sam et al. 2012). 
 Food consumption is not only controlled through neural signals, but certain hormones 
within the endocrine system have been shown to influence energy homeostasis through negative 
feedback loops containing leptin, melanin-concentrating hormone (MCH), and ghrelin. 
Peripheral signals from leptin inhibit NPY-releasing neurons within the hypothalamus that leads 
to a reduction in MCH release form the hypothalamus. A decrease in MCH secretion allows 
appetite signals to potentiate, effectively leading to food intake. Nevertheless, the reverse of this 
process elicits satiety mechanisms, indicating that as leptin signaling decreases MCH signaling 
increases, resulting in the formation of cyclical feeding patterns (Sam et al. 2012).  
 Like its counterpart leptin, ghrelin is a natural ligand of growth hormone that is secreted 
by D cells within the fundus of the stomach to increase food intake and promote weight gain. 
After a person has ingested a meal, ghrelin can facilitate gastric emptying, but as excess adipose 
tissue becomes present, ghrelin secretions begin to decrease to prevent overfeeding. This 
feedback mechanism allows the GI tract to both promote and prohibit the feelings of starvation 
and satiety controlled by the hypothalamus (Delporte 2012).  
 For those who are morbidly obese, there are numerous factors beyond food intake that 
regulate their daily meals. It has become increasingly clear that obesity is hard to combat due to 
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the metabolic changes that adipose tissue can inflict on an obese individual. Within the body 
adipose tissue is responsible for the release of adipokines that interact with energy homeostasis.  
Hardwood and colleagues report leptin secretion via excess adipose tissue begins to increase 
food intake and the silencing of satiety signals. As a result, obesity is a disease that can be self 
sustained and extremely hard to combat (Harwood 2012).  
Melanin-concentrating Hormone 
 Melanin-concentrating hormone (MCH) was discovered in teleost fish where it functions 
to lighten its scales. In mammals, MCH is a highly conserved neuropeptide that is orexingenic 
within the hypothalamus and increases hunger sensations (Pissios and Maratos-Flier 2003). 
MCH also controls other physiological effects such as sleep-wake cycles, voiding behaviors and 
depression (Hassani, Lee, and Jones 2009). In addition to neurological effects, MCH can also act 
upon peripheral tissues such as adipocytes. An increase in leptin mRNA transcription is seen 
with elevated levels of MCH further supporting the cyclic nature of these two metabolic 
hormones (Bradley et al. 2000).  
Melanin-concentrating Hormone Receptor-1 
 In order to affect adipocytes, MCH must first bind to membrane receptors on targeted 
cells. MCH lacks the ability to simply diffuse through the membrane so it must first bind to 
melanin-concentrating hormone receptor-1 (MCHR-1). MCHR-1 is a G protein-coupled receptor 
(GPCR) that is capable of binding several different heterotrimeric proteins including Gi/o and Gq 
allowing for diverse signaling pathways (Gehlert et al. 2009).  
 Secondary signaling pathways activated by MCHR-1 include activation of the 
extracellular-signal-regulated kinase (ERK) pathway and the mitogen-activated protein kinase 1 
pathway (MAPK1). Both ERK and MAPK1 pathways lead to an increase in transcription factors 
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within neural cells, enhancing the MCH signal. In addition, MCH can increase the amount of 
intracellular free Ca 
2+ 
that promotes cell growth, proliferation, and gene transcription (Pissios 
and Maratos-Flier 2003). 
 MCH also affects peripheral tissues such as adipocytes. Bradley and colleagues report 
that 3T3L-1 express MCHR-1 that can bind MCH and activate the ERK pathway. ERK 
activation leads to an increase in adipocyte secretion of leptin, a prominent satiety signal. 
Consequently, leptin expression is up regulated as a result of MCH-MCHR-1 interaction 
indicating a potentially viable target for obesity treatments (Bradley et al. 2000).  
 A challenge in targeting secondary signaling of MCH is the identification of the 
internalization pathway that the MCH-MCHR-1 complex uses. Saito and colleagues investigated 
the possibility of MCHR-1 internalization via clathrin coated vesicles and found that after 
inhibition, only 66% of receptors were not internalizing. These results suggest that non-clathrin-
mediated endocytosis was occurring (Saito, Hamamoto, and Kobayashi 2013). Consequently, 
there may be other mechanisms and areas along the plasma membrane that control MCH-
MCHR-1 internalization.   
Lipid Rafts 
 MCHR-1, along with many other transmembrane receptors, is associated with cholesterol 
and lipid-enriched portions of the plasma membrane of the cell. These areas are described as 
lipid rafts which consist of dynamic assemblies of cholesterol and shpingolipids. Lipid rafts are 
highly hydrophobic areas dispersed throughout the plasma membrane. Both neurons and 
adipocytes have been shown to contain MCHR-1 and other receptors that co localize with lipid 
rafts  enhancing signal amplification (Simons 2001;Cook, Delorme-Axford, and Robinson 2008).  
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 Previous studies have shown that MCHR-1 co localizes specifically with a subset of lipid 
rafts known as caveolae. Caveolae are invaginations found on the cell surface and are indicated 
by lipid enriched regions and the presence of caveolin-1, an integral membrane protein that 
tightly binds cholesterol (Cook et al. 2008). It is speculated that caveolae interacts with MCHR-1 
in two ways. First, caveolae can organize signaling molecules such as MCHR-1, increasing the 
signal generated from MCH binding via signal amplification. Second, caveolae is integral to the 
internalization of these membrane receptors. As a result, MCH/MCHR-1 internalization is 
carried out through the endocytotic pathway where a portion of caveolae will be removed from 
the plasma membrane and arrive in the cytoplasm as an early endosome that can potentiate 
secondary pathways such as the ERK and MAPK1 leading to cellular desensitization (Simons 
2001; Cook et al. 2008).  
 Speculation surrounds this pathway as research continues to show that cellular 
desensitization continues despite the lack of caveolae. Moden and colleagues report that clathrin-
mediated endocytosis may be the primary cause of MCH/MCHR-1 internalization. Clathrin-
mediated endocytosis refers the coating and internalization of a receptor protein complex via 
clathrin, a protein that is involved in vesicle coating. After 30 minutes of MCH exposure, a 44% 
reduction in the initial surface levels of MCHR-1 was observed. Reduction of cell surface 
MCHR-1 indicates the presence of internalization via a clathrin mediated endocytotic pathway 
(Moden et al. 2013). 
 Once the MCH/MCHR-1 complex is internalized either by clathrin or caveolae mediated 
endocytosis, receptors can be degraded or recycled back to the plasma membrane. Because 
MCH/MCHR-1 internalization halts secondary messengers, this process is labeled as 
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homologous desensitization in which a receptor activation-independent pathway is mediated 
through the effects of the secondary messengers it activates. (Ferguson 2001). 
Specific Aims 
 With the increasing prevalence of obesity in the United States and around the world, 
there is a need for targeted treatments that will be able to reduce this epidemic. The effort to end 
obesity is currently being supported by educational outreach programs and health care 
administrators that warn against the dangers of cardiovascular disease and type II diabetes.  
There is promise however, in targeting MCH signaling through MCHR-1 in efforts to 
treat obesity. Past studies have shown that MCHR-1 knockout mice have shown an increase in 
adipose tissue. When knockout occurs, there is a decrease in the satiety signals leading to 
increased caloric intake. As a result, MCH agonist studies have shown that satiety signals will 
indeed increase and lead to a lean body phenotype (Bjursell 2006).  
Despite these past endeavors little is still known about the desensitization mechanisms of 
MCHR-1 and how its co localization with caveole effects MCH internalization. Therefore it was 
the purpose of this to present information on the relationship between caveolae and MCH 
internalization to indicate whether caveolae internalization is important in MCH signaling. In 
order to accomplish this task, three specific aims were undertaken.  
Specific Aim 1  
 Engaging in meaningful research in a lab requires a mastery of certain types of 
techniques. For this research to be successful, correct procedures need to be carried out, in 
particular the generation of a sucrose gradient and western blot analysis. A sucrose gradient is 
imperative to this research because it will allow for the separation of cellular components based 
upon their molecular weight. By creating a useable sucrose gradient caveolae isolation 
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procedures could be carried out that would separate the contents of the cell based upon density. 
Once a successful sucrose gradient was produced, the process of western blotting was carried 
out. Western blotting was used in order to isolate and quantify the caveole present within the 
harvested cells. The intricate steps required to achieve a viable western blot were perfected over 
time and ultimately led to data that could be interpreted.  
Specific Aim #2  
After the techniques needed to illustrate the presence of caveolae, procedures were 
carried out that were aimed at disrupting the formation of caveolae within the plasma membrane. 
The disruption was accomplished using antibiotics, nystatin which is a well known cholesterol 
inhibitor. Overall, our specific aim was directed towards demonstrating the efficacy of nystatin 
treatments on the disruption of caveolae.  
Specific Aim #3  
 Disruption of caveole determined by nystatin treatments would only be applicable to our 
research if an interruption in MCH –MCHR-1 occurs. This disruption of signaling was tested 
through the administration of MCH to cells pretreated with Nystatin. Subsequent tests indicated 
if MCH-MCHR-1 were internalized via the caveolae pathway or if disruption of these lipid rafts 
truly hindered signal transduction. Depletion of caveolae and MCH treatments were the most 
reliable way to show if MCHR-1 co localization with caveolae is a future treatment target.  
Nonetheless, Understanding the relationship between caveolae, MCHR-1 and MCH 
internalization could enhance the knowledge of the mechanism of MCH/MCHR-1desenstization 
and lead to a viable treatment option that can combat the heavy burden of obesity.  
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MATERIALS/METHODS 
Tissue Culture 
 BHK-570 cells (ATCC) were cultured as a tissue monolayer using DMEM
-
 media 
(CellGro) containing 10% fetal bovine serum (FBS) (Atlanta Biological). Cells were fed every 
five days and passaged when they were confluent. Cells were passaged by the addition of new 
media into a culture flask and transfer of cells after the use of trypsin, a serum protease that 
detaches the cells from the old flask. Culture conditions throughout cell proliferation and passage 
were set at 37
°
 C, 5% CO2, and 90% humidity.  
Transfection 
 Cell lines were transfected at 90% confluency in 10cm culture dishes. Transfections were 
carried out following the recommended protocol from SigmaGen utilizing 15 µL of their 
LipoD293 reagent and 5 µg of VSVg MCHR-1 plasmid. Media was changed 1 hour pre-
transfection and experiments were run approximately 72 hours post transfection.  
Expansion of Transfection 
 Once cells within a 10cm dish were 90% confluent and transfected, media was aspirated 
off and cells were transferred to a 50 mL conical vial containing 45 mL of DMEM
-
 and 10% 
FBS. The solution was vortexed and 8 mL was added to six 10 cm dishes. Cells were allowed to 
grow to 60% confluency over 24 hours.  
Nystatin Treatments 
 Nystatin treatments were used for half of the 60% confluent dishes. Nystatin treatments 
with a concentration of 60 µg/µl, were added to 3 mL of DMEM
-
 media in attempts to reduce the 
complete absence of cholesterol and caveolae within the plasma membrane. Nystatin treatments 
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were for 30 minutes and conditions were set at 37
°
 C, 5% CO2, and 90% humidity. Normal 
DMEM
-
 media was added to the three untreated 10 cm dishes as a control.  
MCH Treatment  
Once cells were treated, MCH treatments were carried out for 10 minutes and 30 minutes. 
In 8 mL of DMEM+10% FBS media, 1 µM of MCH was added. Old media within the 10 cm 
dishes was aspirated off and MCH solution was added for desired amount of time.  
Homogenate Preparation 
 After 30 minutes of incubation, media from treated and untreated dishes was aspirated 
off. All 6 dishes were washed twice with 5 mL of cold phosphate buffered saline (PBS). PBS 
was made by adding 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 2.4 g KH2PO4 to 800 mL of ddH2O. 
Once the second wash was aspirated off of treated and untreated dishes, 2 mL of 500 mM 
sodium carbonate (pH 11) was added to 1:1000 protease inhibitor (Thermo Scientific) to create a 
protease/phosphatase inhibitor cocktail. The mixture was vortexed and 1 mL was added to 1 dish 
of nystatin-treated cells and the remaining 1 mL was added to 1 dish of the untreated cells. Using 
a cell scraper, the cells were removed from the bottom of the both the treated and untreated dish 
and became suspended in the media. The media was then transferred to the next dish that 
contained the same type of cells of the first dish. After a second scrape, the media was added to 
the final dish that produced a concentrated amount of treated and untreated cells. Treated and 
untreated cell lysates were added to separate Dounce homogenizers on ice. Each was 
homogenized for 10 strokes and then sat for 2 minutes before 2 more homogenizations were 
carried out with 2 minute in between. All above procedures were performed on ice.  
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Sucrose Gradient Generation 
 In order to separate the lysates based upon density, the homogenate was loaded into a 
sucrose gradient that was of differing densities. Post homogenation, 2 mL of treated and 
untreated lysates were loaded into separate ultracentrifugation tubes with 1 mL of 90% sucrose 
(9.9g of Sucrose and 11 mL of ddH2O). The ultracentrifugation tube was then vortexed to make 
45% sucrose solution (1mL of 90% sucrose and 2 mL of homogenate). After vortexing, 4 mL of 
35% sucrose was added to the tube drop wise as to not disturb the denser layer. To bring the 
gradient up to 12 mL, 4-5 mL of 5% sucrose was added drop wise to the tube. 35% and 5% 
solutions were made in an MBS buffer made by dissolving 97.6 g MES (free acid) in 800 mL of 
ddH2O, bringing up the volume to 1 L with ddH2O. pH was adjusted for solution using 10 N 
NAOH. Both tubes were then weighed in order to balance them as to prevent anomalies during 
ultracentrifugation. 
Ultracentrifugation 
 Treated and untreated sucrose gradients were placed into titanium tube holders and 
attached to a SW-41 swinging bucket rotor. The bucket was attached to the ultracentrifuge and 
was run at 39,000 rpm for 18 hours at 4
°
C.  
Fraction Collection and Preparation 
 Post ultracentrifugation, (12) 1mL fractions were removed from the tubes starting from 
the top of the gradient and moving towards the bottom. Fractions were stored in the freezer 
overnight. After 24 hours, 25 uL of 5X Lamaelli sample buffer was added to each fraction. 
Lamanelli sample buffer was made by adding 1.5 g SDS to 3.75 ml 1M Tris (pH 6.8) 
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, 0.075 g bromophenol blue, 480 µl of BME, 7.5 mL of glycerol, and 7.5 mL of H2O. A 100 µL 
of each fraction was removed and placed in a boiling water bath for 2 minutes. Fractions were 
then spun in a microcentrifuge for 2 minutes at 13,000 rpm and 4
°
C.  
Bradford Protein Analysis 
Fractions were then placed in a 96 well plate for confirmation that protein existed. The 
first two rows of wells were filled with 20 µL of Bovine Serum Albumin (BSA) standard 
followed by two rows with 20 µL of untreated fractions and two rows of 20 uL treated fractions. 
In addition, 200 µL of 1X Bradford reagent was added to each well. Bradford reagent was made 
by adding 100 mg Coomassie blue to 50 mL of 90% ethanol, 100 ml of 85% phosphoric acid 
along with 50 mL of ddH2O. The 96 well plate was read 595nm using a Synergy 1 plate reader.  
Gel Electrophoresis and Wet Transfer 
 A Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS/PAGE) apparatus 
was prepared. In order to generate two 75mm 12% gels, a 12% running solution and a 4% 
stacking solution were made. For the 12% running buffer, 3.0 mL of 40% BIS Acrylamide along 
with 2.5 mL of 4X TrisCl/SDS (pH 8.8), 33 µL of 10% APS and 4.5 mL of ddH2O were mixed. 
The stacking buffer was made by combining 0.5 mL of 40% BIS Acrylamide, 1.25 mL of 4X 
TrisCL/SDS (pH 6.8), 25 µL of 10% APS and 3.20 mL of ddH2O. The addition of 6.6 µL of 
Tetramethylethylenediamine (TEMED) to the running solution polymerized the gel after 30 
minutes of being loaded into the constructed apparatus. After polymerization, 6 µL of TEMED 
was added to the stacking solution and was added on top of the polymerized running solution 
within the apparatus. Plastic spacers were then inserted to create wells within the gel. After a 
subsequent 30 minutes, 40 µL of the prepared samples were loaded into 12 separate wells along 
with 5 µL of a protein ladder (BIO-RAD) in 2 separate gels, one for untreated one for nystatin 
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treated. The SDS/PAGE ran at 150 V for 110 minutes.  Post SDS/PAGE, both gels was placed 
between separate filter paper and a nitrocellulose membrane that were then placed in a transfer 
buffer for 15 minutes. The transfer buffer was prepared by adding 11.6 g glycine, 23.2 g Tris 
Base, 1.48 g SDS, and 800 mL methanol in 1 L of water which was brought to 5 L with the 
addition of 4 L of water. The wet transfer apparatus ran for 45 minutes at 350 mA.  
Western Blot Analysis  
 After the completion of the wet transfer, both nitrocellulose membranes were blocked in 
10 mL of 5% dry milk made from 1 g of powdered milk and 20 mL of Tris-Buffered Saline-
Tween (TBS-T) for 1 hour. TBS-T was made through the addition of 250 µl of TWEEN to 200 
mM Tris-Cl, and 1.4 M NaCl. Post blocking, both membranes were treated with a 1:1000 
dilution of Rabbit Anti-Cavelolin-1 Antibody (BioRad). Membranes were stored in cold room 
4°C overnight. The primary antibody was removed through three 10 minute washes of the 
membranes with 5 mL TBS-T preparing membranes for the secondary antibody treatment. The 
secondary antibody used was a 1:10,000 dilution of Goat Anti-Rabbit Antibody (BioRad). The 
secondary antibody procedure lasted 45 minutes followed by another three 10 minute washes 
with 5 mL TBS-T.  
Chemiluminescent and Development  
Membranes were prepared for fixation and development according to the ECL kit 
protocol provided by Thermo Scientific. Membranes were transferred to a dark room where 
development and fixation of the proteins was carried out and a film developed on KODAK film.  
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RESULTS 
Designing a Strategy to Disrupt Caveolae  
MCH has been shown to play an integral role in regulating energy homeostasis. Studies 
have shown that MCH knockout mice contain a lean phenotype indicating MCH’s role in food 
consumption. MCH can bind to MCHR-1 or and internalize via clathrin or caveolae mediated 
endocytosis (Razani et al. 2002; Cook, Delorme-Axford, and Robinson 2008). Further, MCHR-1 
has been shown to activate multiple signaling pathways through the activation of Gq, Gi, and G0 
proteins. In addition MCHR-1 has been shown to co localize with caveolae lipid rafts within the 
plasma membrane (Moden et al. 2013).  
To further understand how MCHR-1 disruption can lead to decreased internalization of 
MCH, caveolae lipid rafts must be disrupted. The antibiotic Nystatin has been shown to be a 
viable cholesterol inhibitor that can be used to disrupt co-localization of caveolae and MCHR-1. 
A recent study by Hussain and colleagues utilized nystatin to disrupt the plasma membrane of 
host cells in attempts to disrupt the entry of the human enterovirus (HEV71). Reduction in 
infection indicated that nystatin treatments did indeed disrupt functional receptor localization to 
the plasma membrane providing evidence that nystatin was an effective pharmacological tool 
(Hussain et al. 2011).  
With previous research by Hussain and colleagues confirming its validity, nystatin, was 
used in attempts to sequester caveole and disrupt its co-localization with MHCR-1. Confluent 
BHK-570 cells were treated with Nystatin over a 30 minute period. Cell lysis and 
ultracentrifugation were used to separate caveolae from the different parts of the cell.  
The main structural component of the lipid raft caveolae is a protein known as caveolin-
1. Consequently, a protein assay known as a Bradford analysis was used to show 1) The presence 
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or reduction of caveolin-1 within the cell 2) the determination of how much total protein was 
present in each fraction. 
 
A) Amount of Total Protein in Each Fraction          B) Previous Bradford Analysis  
 
 
 
  
  
 
When compared to studies carried out by Cook and colleagues, total protein 
concentration within the fractions is normal for untreated cells. As seen in Fig 1A. there was a 12 
mg increase in protein presence from fraction 4 compared to fraction 5 in untreated cells. 
Further, higher protein amounts were seen in fractions 10-12 for both untreated and nystatin due 
to the high density of most proteins within the cell. Both dishes were assumed to have the same 
total protein content as they were grown under the same conditions for equal amount of time. 
Being able to reproduce already published results (Fig 1B) increased the validity of this data and 
allowed for secondary experiments to proceed. It is important to note that Bradford analysis of 
the separated sucrose gradients yielded total protein concentration, not just the presence of the 
caveolae protein.  
 
 
Figure 1: A) Bradford Analysis of Untreated and Treated Cells indicates a shift in protein fraction amount. BHK-570 cells were 
either treated with 60 ul/ug of Nystatin for 30 minutes or left untreated. Cell lysis and ultracentrifugation were completed followed by a 
Bradford analysis. Nystatin treatments show a shift in protein amount, specifically in fractions # 4, 5, 6, and 7.  B) Previous Bradford 
Analysis of Untreated BHK-570 Cells performed by (Cook et al. 2008) indicates that there is indeed an increase of total protein 
content within fractions #4,5,6. 
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Percent of Total Protein in Each Fraction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Through Bradford analysis, the percentage of protein within each fraction was able to be 
calculated. This calculation was necessary to show that as expected, nystatin shifted protein 
content into higher fractions. As seen in Fig 2., the increase in protein content in fractions 6 and  
7 was a direct result of nystatin as its presence within the plasma membrane made the proteins 
more dense resulting in a shift to higher fractions. Subsequent analysis of the Bradford data 
indicated that fraction 4 experienced a 50% increase in protein content after nystatin treatments 
while fraction 5 had a 50% decrease in protein. Fraction 6 remained relatively unchanged while 
fraction 7 experienced a 35% increase in protein concentration after nystatin treatments. Again 
Bradford analysis only calculated total protein percentage and not just the percentage of caveolae 
within the fractions.   
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Figure 2: Bradford Analysis of Untreated and Treated Cells indicates a change in the percentage of protein within 
fractions. BHK570 cells were either treated with Nystatin for 30 minutes or left untreated. Cell lysis and ultracentrifugation led to 
fraction collection and subsequent Bradford analysis. Analysis revealed that percent of protein within certain fractions was altered. 
Again, fractions # 4, 5, 6, and 7 were particularly affected.  
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Caveolae invaginations within the plasma membrane are coated with a marker protein 
known as caveolin-1 (CAV-1). Early endosomes of the caveolae mediated endocytoic pathway 
are coated with CAV-1 indicating, the strong relationship between caveolae and CAV-1.  
 Also associated with caveolae is cholesterol that makes the lipid rafts highly stiff. 
Increased rigidity can potentiate the signals caused by hormones either through endocytosis or 
secondary signaling. When cholesterol is absent, membrane fluidity increases, inhibiting the 
presence of viable signaling mechanisms which may decrease the effects of hormones. 
Cholesterol sequestration is a direct target of certain antibiotics in attempts to disrupt plasma 
membrane formation and signaling. Nystatin is an antibiotic that acts through cholesterol 
sequestration that produces abnormal plasma membrane behavior that leads to cell death in 
bacteria (Lampan et al. 1962).  
 When administered in small doses to BHK-570 cells, nystatin can be a potent inhibitor of 
normal cholesterol formation within the plasma membrane (Hussain et al. 2011). As a result of 
nystatin treatments, cholesterol enriched caveole regions decrease reducing the presence of 
CAV-1. Consequently, western blot analysis that indicates the presence of CAV-1 through use of 
antibodies should show a decrease in CAV-1 in nystatin treated cells.  
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A) Western Blot Analysis of Untreated and Nystatin Treated BHK-570 Cells B)  
    
  
  
 
 
 
 
 
 
 
B) Previous Research : Western Blot Analysis of Untreated BHK-570 Cells 
 
 
 
 
 
 
 
 
 
 
Figure 3: A) Western Blot analysis reveals that CAV-1 is reduced within Nystatin treated BHK-570 cells. Fractions of both 
untreated and treated cells were subjected to SDS/PAGE. After completion, gel was subjected to wet transfer process that moved 
protein from gel to nitrocellulose membrane. Membrane was blocked and then treated with a 1:5000 dilution of 1° Rabbit 
Anticaveolin-1 antibody and allowed to treat overnight. Membrane was then treated with 2° Goat Antirabbit antibody and 
subjected to chemiluminesence and development and fixation in order to make the CAV-1 bands visible. Picture presented shows 
bands present at 25 kDA. B) Western Blot analysis of BHK-570 cells blocked for CAV-1 conducted by (Cook et al. 2008) 
illustrated dark bands within fractions 4 and 5 at the 25 kDA marker indicative of CAV-1.  
 
 Western blot analysis was carried out after SDS/PAGE and antibody treatments. The use 
of a chemiluminescent kit illustrated the presence of CAV-1 within fractions. Fig 3.A indicated 
dark banding within fractions 1, 5 and 6 of the untreated cells while light banding occurred in 
fraction 1 in the treated cells. The absence of banding in other fractions is indicative of the loss 
or shift in caveolae due to nystatin. Unlike the Bradford analysis, western blotting allowed for 
the identification of one specific protein instead of the total content within fractions. For this 
study, comparing Bradford analysis in Fig 1A data to western blot results (Fig 3A) shows that 
protein was present within all fractions but CAV-1 was only in certain areas of the sucrose 
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gradient. Results of this study were also compared to previous research done by Cook et al. 2008 
in order to increase its validity as a successful western blot.   
MCH treatment after Caveolae Disruption 
 After a standard protocol produced adequate caveolae disruption, timed MCH treatments 
were carried out in order to investigate if MCH internalization was disrupted. Previous research 
has indicated that MCHR-1 localization within caveole membranes may play a role in signal 
internalization or that internalization is completely independent of this pathway(Moden et al. 
2013). In order to test this postulate it is crucial to identify MCHR-1 co localization with 
caveolae and then determine whether after timed MCH treatments, there is a significant decrease 
of MCHR-1 on the plasma membrane. Because BHK-570 cells lack an endogenous MCHR-1, 
transfection of a VSVg-MCHR-1 was carried out. After cells were grown to confluence, both 
untreated and treated cells were subjected to MCH treatments of 0, 10, and 30 minutes. 
Subsequent ultracentrifugation, SDS/PAGE, and western blot analysis illustrated the effect of 
MCH treatments on MCHR-1 and caveolae presence within the fractions.  
 
 
 
 
 
 
 
 
 
22 
 
A) Isolated Fractions: VSVG-MCHR1                        B) Isolated Fractions: CAV-1 
 
   
 
 
 
 
 
 
 
 
C) Previous Research 
 
 
  
 
     
 
 
 
 
 
Fig 4: A) Isolated Fractions of Untreated Cells blocked for VSVG-MCHR-1 indicated a heavy presence of VSVg-MCHR-1 
receptor within fractions 4 and 5.At 10 minutes, of MCH exposure, VSVg-MCHR-1 localizes to fractions 4 and 5. The majority 
of MCH receptor localizes to fraction 4 at 0 minutes of exposure (data not shown) with a molecular weight up shift after 10 
minutes, illustrated by the dark banding in fraction 5. After 30 minutes, VSVg-MCHR-1 is still present within fraction 5 
indicating that there is still an increase in molecular weight. Banding was present at 72-55 kDa. B) Isolated Fractions of 
Untreated Cells blocked for CAV-1 indicated an increased presence of CAV-1 within the fractions that were previously shown 
to show VSVg-MCHR-1. Banding occurred at 25 kDa. C) Previous Research has shown that VSVg-MCHR-1 is primarily 
associated with fractions 4 and 5. Cook et al. 2008 illustrated the presence of both VSVg-MCHR-1 and CAV-1 within fractions 
4 and 5.  
 
 
 Western blot analysis revealed that CAV-1 and VSVg-MCHR-1 are highly co-localized 
showing up in the same fractions during timed MCH treatments. CAV-1 is present throughout 
MCH exposure and its co-localization with MCHR-1 is evident in fractions 4 and 5 at 0-minutes 
(data not shown), in fractions 4,5,and 6 at 10-minutes and in fraction 5 at 30-minutes MCH 
exposure.  The previous research conducted by Cook et al. 2008 served as a comparison in order 
to validate the success of the experiment (Fig 4C). Nonetheless, all blots presented are of 
Fraction 
  1    2    3    4   5    6       MCH exposure (min.) 
 
             10 
 
 
 
 
             30 
 
 
 
Fraction 
 1  2   3   4  5 6 
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untreated BHK-570 cells. Data collected on cells treated with nystatin are hard to interpret due to 
a high amount of background within the developed pictures. It is the goal of future research to 
prevent this interference and present reliable data that describes the relationship between VSVg-
MCHR-1 and MCH co-localization and internalization.  
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DISCUSSION 
Sucrose Gradient Generation and Western Blot Analysis procedures were mastered correctly 
 It was crucial for this study to adequately produce sucrose gradients and western blot 
analysis that quantified protein content as well as the presence of caveolae. The sucrose gradient 
was considered a success because the untreated cells expressed about the same curve as Cook et 
al. had previously shown. Previous research by Cook and colleague has also indicated that 
caveolae and lipid rafts tend to separate within fractions 4, 5, and 6 of the sucrose gradient based 
upon their molecular weight (Cook et al.2008). This information allowed for the further 
investigation of fractions 4, 5, and 6 throughout the study and when these regions are compared 
between untreated and treated cells, there seems to be a difference. 
 Treated cells showed a shift in protein content near fractions 4, 5 and 6 which was 
expected as the presence of nystatin altered the density and formation of the lipid rafts. 
Alteration was shown in Fig 1A by a plateau between fractions 4, 5 and 6. When compared to the 
untreated cells, which only show an increase in protein content at fraction 5, there seems to be 
some disruption within the lipid raft region due to the presence of nystatin. Within fractions 4-6 
of nystatin treated cells there is a 62% increase in protein content from untreated cells (Fig 2). 
Results from the Bradford analysis indicated that protein within the nystatin treated cells may 1) 
be more abundant because of an increased number of cells when lysed or 2) The presence of 
nystatin caused a shift of protein in the lipid raft region due to its ability to sequester cholesterol. 
Subsequent western blot analysis was a success as the presence of caveolae was clearly shown 
by dark banding in the 25 kDa region of the untreated cells in fractions 5 and 6 (Fig 3A). 
 Despite the mastery of these techniques, challenges surrounded this portion of the study. 
In order to generate a polymerized gel that could separate the protein based upon weight the 
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exact concentrations of the running and stacking solutions had to be used. At times gels were too 
thin due to the lack of TEMED added. Thinner gels resulted in the loss of caveolae as it travelled 
too far down the gel and was lost before transfer. Therefore, when an adequate gel was produced 
the exact amount of TEMED was recorded and served as the standard for the remainder of the 
study.  
 Cell number also posed a challenge for this study. In order to generate enough cells to 
express cav-1 at detectable levels, BHK-570 had to be grown for 48 hours on 10 cm culture 
dishes. The issue arose when the cells were lysed and there were no prior controls used to 
determine if both the untreated and the treated had the same number of cells. Increased cells 
within either the untreated or treated may have contributed to an increased expression of 
caveolae. Increased expression of caveolae because of a greater cell number limits the 
conclusions that support the efficacy of nystatin treatment. Future studies will include use of a 
hemocytometer, a device that is used to calculate the exact number of cells (Van der Linden et al. 
2014). Knowing that both the untreated and treated experiments contain the same number of 
cells will make future conclusions surrounding the effectiveness of pharmacological membrane 
disruptors much stronger.  
Cholesterol depletion with nystatin alters the formation and presence of caveolae 
 In bacteria, nystatin has been shown to disrupt the plasma membrane and lead to cell 
death (Lampen et al. 1962). Within BHK-570 cells, however, nystatin is used to deplete 
cholesterol which effectively disassembles caveolae lipid rafts. If MCHR-1 were enriched in 
caveolae, lipid raft disruption would subsequently be expected to alter signaling. A decrease in 
caveolae was shown by blocking for caveolin-1 (cav-1), a structural protein of caveolae. 
According to Fig 3A, 1.5 hour exposure to 60 µg/µl of nystatin can effectively deplete the 
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plasma membrane of caveolae. The absence of dark banding in fractions 5 and 6 that were 
present in untreated cells, indicate that nystatin treatments can effectively decrease the amount of 
caveolae. 
 Previous research has shown that antibiotic treatments can severely deform cellular 
structure leading to a decrease in proper plasma membrane formation (Cook et al. 2008). The 
lack of proper formation of lipid rafts instead of complete caveole destruction seems to be the 
best conclusion of this study. Even though cav-1 is not present within the western blot, the 
Bradford analysis shows a strong presence of protein in nystatin treated cells. These results are 
indicative of cav-1 being present but in smaller amounts and spread throughout fractions 4, 5 and 
6. According to Fig 2., there is approximately four times the amount of protein within fraction 5 
of the untreated cells when compared to fraction 4. Coupled with the blot analysis shown in Fig 
3.A. this spike is indicative of cav-1 present in fraction 5. When examining the nystatin treated 
cells, fraction 5 contains 50% less protein (Fig 2.) which may account for the light band seen on 
the blot (Fig 3.A). Nevertheless, the presence of nystatin is shown to alter the localization of cav-
1to caveolae fractions on sucrose gradients.  
MCHR-1 localization to caveolin-1 enriched fractions is independent of 0.250-uM MCH 
treatment at 10 minutes with equal protein content 
 Exposure to 1 µM MCH appeared to have no effect on receptor localization to caveolin-1 
fractions within 10 minutes or 30 minutes. Fig 4 A, B indicates the presence of a properly 
expressed VSVg-MCHR-1 within BHK-570 cells along with its co-localization to cav-1 and its 
presence in the 30 minute MCH treatment time. Unfortunately, data for 0- minutes could not be 
shown due to increased interference on the blot, like the 10-minute exposure time, both MCHR-1 
and cav-1 remained localized to fractions 4 and 5. A hypothesized explanation for this data is 
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that the receptor has not yet undergone internalization from the plasma membrane and remains 
within lipid rafts at 10-minutes. To test this, a longer time course of hormone treatment was 
carried out.  
 After 30 minutes of exposure, MCHR-1 seemed too localize primarily within fraction 5 
indicating that an up shift in molecular weight of MCHR-1 (Fig 4A). This up shift could be due 
to MCH/MCHR-1 interaction as well as the preparation for caveolar mediated internalization 
which is initiated by post translational modifications of MCHR-1 (Saito, Hamamoto, and 
Kobayashi 2013). As a result, prolonged hormone treatments may show that internalization via 
caveolae does occur. 
 Previous research Moden et al. indicates that MCHR-1 and cav-1 do co-localize and 
prolonged hormone treatments produce MCH internalization. Moden et al. reports that after 30 
minutes of MCH treatment, 62% of surface MCHR-1 was internalized. Whether this process is 
caveolae or clathrin mediated remains to be determined suggesting that even if caveolae was 
depleted there still will be receptor internalization (Moden et al. 2013). Consequently, no 
conclusions can be made regarding the effect of cholesterol depletion, and subsequent 
destruction of caveolae on MCHR-1 internalization.  
 The lack of a conclusion within this study is also due in part to the lack of data presented 
on nystatin treated cells. The MCH treatments performed were done on untreated cells in 
attempts to establish a viable protocol for future studies on nystatin cells. It is the hope that this 
project will pursue hormonal studies on treated cells in order to establish a clear relationship 
between MCHR-1 caveolae co-localization and MCH internalization.  
 Other technical errors prevented strong conclusions to be stated. Some procedures 
presented were only replicated twice bringing into question their validity as normally accepted 
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studies can be replicated numerous times by the primary investigator or other research 
institutions. In addition, fraction separation could have been altered within both experiments as 
pipetteing techniques for this type of collection is difficult to control. 
Future Directions 
 There are several potentially promising directions that this project could take. First, the 
use of siRNA to delete cav-1 solely rather than pharmacological cholesterol depletion can be 
carried out. Oh and colleagues have previously shown that cav-1 siRNA has severely inhibited 
the proper formation of caveolae enriched regions within the plasma membrane. Decrease in 
these regions could decrease the co-localization between caveolae and MCHR-1 (Oh and 
Schnitzer 2001). This genetic alteration, however, could have ill advised side effects on the cell 
that may inhibit other functioning pathways. Second, other pathways that are affected by MCH 
can be investigated before and after caveolae depletion. These pathways include MAPK1 which 
regulates secondary signaling within the cell that can lead to desensitization.  
 Third, the use of an endogenous cell line, such as the 3T3L-1 pre-adipocyte or 
differentiated adipocyte, is critical for assessing the functional role of MCHR-1 in caveolae. 
Fourth, the role of MCHR-1 may also be affected by phosphorylation. As indicated by data there 
is an upshift in molecular weight during 30 minute treatment time (Fig 4A). We hypothesize as 
do others, that this molecular up shift could have been caused by the phosphorylation of MCHR-
1 after MCH binding. Saito and colleagues report that the receptor phosphorylation and 
subsequent binding of β-arrestin prevent consequent interactions of the receptors with G-
proteins, thereby effectively terminating the G-protein-mediated signaling and initiating the 
endocytic process (Saito, Hamamoto, and Kobayashi 2013). This phosphorylation activity can be 
an effective target for future investigations and treatments concerning MCH. If MCHR-1 can be 
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constitutively phosphorylated, desensitization could lead to a viable treatment option in 
combating the obesity epidemic.  
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